Research programme: anti-CD55 antibodies - Genesis Biopharma

Drug Profile

Research programme: anti-CD55 antibodies - Genesis Biopharma

Alternative Names: Anti-CD55 antibody - Genesis Biopharma; Anti-DAF antibody - Genesis Biopharma; GBP-102; VG 102 - Genesis Biopharma

Latest Information Update: 24 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research Technology
  • Developer Genesis Biopharma
  • Class Antibodies
  • Mechanism of Action CD55 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Lymphoma

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top